Half-Life Cancer Research Results

Half-Life, Half-Life: Click to Expand ⟱
Source:
Type:
For many drugs, the half-life is the time it takes for half of the drug’s active substance to be eliminated from the bloodstream.
In medicine, knowing a drug’s half-life helps in designing treatment regimens that reduce adverse effects.
Scientific Papers found: Click to Expand⟱
5455- AF,    Ridaura
- Study, PSA, NA
Dose↝, Half-Life↝,
5443- AG,    Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers
- Human, Nor, NA
*Dose↝, Half-Life↝, *toxicity↓,
3155- Ash,    Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera
- Review, Var, NA
Half-Life↝, Inflam↓, antiOx↓, angioG↓, ROS↑, BAX↑, Bak↑, E6↓, E7↓, P53↑, Casp3↑, cl‑PARP↑, STAT3↓, eff↑, HSP90↓, TGF-β↓, TNF-α↓, EMT↑, mTOR↓, NOTCH1↓, p‑Akt↓, NF-kB↓, Dose↝,
5373- ATO,    arsenic trioxide
- Human, APL, NA
Half-Life↝,
5445- ATV,    Atorvastatin
- NA, Nor, NA
*cardioP↑, *LDL↓, HMG-CoA↓, Half-Life↝, BioAv↓, Dose↝,
2716- BetA,    Cellular and molecular mechanisms underlying the potential of betulinic acid in cancer prevention and treatment
- Review, Var, NA
AntiCan↑, TumCD↑, TumCCA↑, ROS↑, NF-kB↓, Bcl-2↓, Half-Life↝, GLUT1↓, VEGF↓, PDK1 / PDPK1↓,
5676- BML,    Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake
- in-vivo, NA, NA
Half-Life↝, Dose↝, Dose↝,
5825- CAP,    Bioavailability of capsaicin and its implications for drug delivery
- Review, Var, NA - Review, Arthritis, NA - Review, Obesity, NA
*AntiCan↑, *TRPV1↑, *cardioP↑, AntiCan↓, Apoptosis↑, ChemoSen↑, *Inflam↓, *Pain↓, *AntiAg↑, *Weight↓, *BioAv↑, BioAv↑, Half-Life↝, Half-Life↓,
5879- CAR,    Pharmacokinetic analysis of thymol, carvacrol and diallyl disulfide after intramammary and topical applications in healthy organic dairy cattle
- in-vivo, Nor, NA
*Dose↝, Half-Life↝, Half-Life↝, Half-Life↝,
6024- CGA,    Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up
- Trial, GBM, NA
*toxicity↓, Half-Life↝, BBB↑,
7417- CS,  CGA,    Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans
- Trial, Nor, NA
Dose↝, BioAv↝, Half-Life↝,
7418- CS,  CGA,  CA,  FA,    Absorption and metabolism of bioactive molecules after oral consumption of cooked edible heads of Cynara scolymus L. (cultivar Violetto di Provenza) in human subjects: a pilot study
- Study, Nor, NA
Half-Life↝, Half-Life↝, Half-Life↝,
6195- Cuc,    Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends
- Review, Var, NA
TumCG↓, Apoptosis↑, TumCCA↑, TumMeta↓, angioG↓, chemoPv↑, BioAv↓, Half-Life↝, cycD1/CCND1↓, cycE/CCNE↓, Casp3↑, cl‑PARP↑, JNK↑, Akt↓, ERK↓, survivin↓, XIAP↓, Bcl-2↓, Mcl-1↓, ROS↑, NRF2↓, FAK↓, MMP9↓, VEGF↓, VEGFR2/KDR/Flk1↓, *NF-kB↓, TLR4↝, NLRP3↑, Pyro↑, GSH↓,
6185- Cuc,    Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics
- Review, Var, NA - Review, Arthritis, NA - Review, AD, NA
*Inflam↓, *antiOx↑, *hepatoP↑, *neuroP↑, *AntiCan↑, *toxicity↝, *BioAv↓, *HO-1↑, *NRF2↑, *NLRP3↑, *SOD↑, *SOD1↑, *ROS↓, *AntiAge↑, *ARE↑, *STAT↓, *NF-kB↓, *neuroG↑, *memory↑, ROS↑, NLRP3↑, CIP2A↓, Akt↓, STAT3↑, VEGFR2/KDR/Flk1↓, DNMTs↓, MAPK↓, YAP/TEAD↓, PI3K↓, Wnt↓, NOTCH↓, TumCCA↑, TumCG↓, TumCP↓, FAK↑, MMP9↓, TumAuto↑, toxicity↝, BioAv↓, Half-Life↝, BioAv↑, selectivity∅,
2809- CUR,    Comparative absorption of curcumin formulations
- in-vivo, Nor, NA
BioAv↑, BioAv↑, BioAv↑, BioAv↑, BioAv↑, BioAv↓, Half-Life↝,
6591- DAS,    Dasatinib in solid tumors
- Review, Var, NA
Src↓, PDGF↓, ABL1↓, BioAv↝, Half-Life↝, Dose↝, eff↑,
6679- DCA,    GSTZ1 genotypes correlate with dichloroacetate pharmacokinetics and chronic side effects in multiple myeloma patients in a pilot phase 2 clinical trial
- Trial, Melanoma, NA
PDK1 / PDPK1↓, Half-Life↝, eff↑, NP/CIPN↑, Dose↝, Half-Life↝,
6694- DFC,    Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent
- Review, Var, NA
COX2/PTGS2↓, PGE2↓, angioG↓, ChemoSen↑, RadioS↑, Dose↝, toxicity↝, toxicity↝, BioAv↑, Half-Life↝, lactateProd↓, eff↑, *AntiAg↑,
6363- DRE,    Therapeutic Potential of Dandelion (Taraxacum officinale) Root Extract in Colon Cancer: A Comprehensive Review
- in-vitro, CRC, NA
Apoptosis↑, *Inflam↓, TLR4↓, NF-kB↓, *GutMicro↑, mtDam↑, *ROS↓, Casp1↑, TNF-α↑, Bcl-2↓, PARP↓, MMP↓, Cyt‑c↓, Casp3↑, TumVol↓, COX2/PTGS2↓, iNOS↓, ROS↑, selectivity↑, TumCMig↓, TumCI↓, ER Stress↑, PERK↑, eIF2α↑, ATF4↑, CHOP/DDIT3↑, TumCCA↑, cycD1/CCND1↓, P21↓, P53↑, BioAv↝, Half-Life↝,
6782- EGCG,    Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability
- Human, Nor, NA
*Dose↝, BioAv↝, Half-Life↝,
6789- EGCG,    Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?
- Review, Var, NA
BioAv↓, Half-Life↝, Half-Life↝, BioAv↝, *BioAv↑, *BioAv↓, *BioAv↑, *BioAv↑, *Dose↝, *toxicity↝,
2561- EGCG,  ASA,    Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment
- ex-vivo, Nor, NA
AntiAg↑, eff↑, Half-Life↝, other∅,
2824- FIS,    Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics
- Review, Var, NA
*antiOx↑, *Inflam↓, angioG↓, BioAv↓, BioAv↑, TumCP↓, TumCI↓, TumCMig↓, *neuroP↑, EMT↓, ROS↑, selectivity↑, EGFR↓, NF-kB↓, VEGF↓, MMP9↓, MMP↓, cl‑PARP↑, Casp7↑, Casp8↑, Casp9↑, *ROS↓, uPA↓, MMP1↓, Wnt↓, Akt↓, PI3K↓, ERK↓, Half-Life↝,
2825- FIS,    Exploring the molecular targets of dietary flavonoid fisetin in cancer
- Review, Var, NA
*Inflam↓, *antiOx↓, *ERK↑, *p‑cMyc↑, *NRF2↑, *GSH↑, *HO-1↑, mTOR↓, PI3K↓, Akt↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, P21↑, p27/CDKN1B↑, JNK↑, MMP2↓, MMP9↓, uPA↓, NF-kB↓, cFos↓, cJun↓, E-cadherin↑, Vim↓, N-cadherin↓, EMT↓, MMP↓, Cyt‑c↑, Diablo↑, Casp↑, cl‑PARP↑, P53↑, COX2/PTGS2↓, PGE2↓, HSP70/HSPA5↓, HSP27↓, DNAdam↑, Casp3↑, Casp9↑, ROS↑, AMPK↑, NO↑, Ca+2↑, mTORC1↓, p70S6↓, ROS↓, ER Stress↑, IRE1↑, ATF4↑, GRP78/BiP↑, eff↑, eff↑, eff↑, RadioS↑, ChemoSen↑, Half-Life↝,
6572- Ger,    Pharmacokinetics of Geraniol and Its Metabolites in Mice After Oral Administration
- in-vivo, Nor, NA
BioAv↝, BBB↑, BioAv↝, Half-Life↝,
7523- HCA,    Inhibition of ATP Citrate Lyase by Hydroxycitrate-Loaded Exosomes Suppresses the Survival of Lung Adenocarcinoma Cells
- in-vitro, Lung, NA
ACLY↓, BioAv↓, Dose↝, TumCP↓, FASN↓, IDH1↓, Apoptosis↑, ROS↑, Half-Life↝,
7468- HNK,    Honokiol and Its Emerging Role in Breast Cancer Therapy
- Review, BC, NA
*ROS↓, *Inflam↓, CSCs↓, ChemoSen↑, BioAv↑, ROS↑, MMP↓, mtDam↑, TumCCA↑, cycD1/CCND1↓, CDK4↓, Casp3↑, Casp9↑, Bcl-2↓, Bcl-xL↓, BAX↑, p‑STAT3↓, AMPK↑, miR-34a↑, EMT↓, HH↓, Shh↓, Gli1↓, PTCH1↓, NF-kB↓, TNF-α↓, IL6↓, Glycolysis↓, GlucoseCon↓, BioAv↓, BioAv↓, Half-Life↝,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2/KDR/Flk1↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2/PTGS2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP/DDIT3↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp/ABCB1↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
2885- HNK,    Honokiol: a novel natural agent for cancer prevention and therapy
NF-kB↓, STAT3↓, EGFR↓, mTOR↓, BioAv↝, Inflam↓, TumCP↓, angioG↓, TumCI↓, TumMeta↓, cSrc↓, JAK1↓, JAK2↓, ERK↓, Akt↓, PTEN↑, ChemoSen↑, chemoP↑, COX2/PTGS2↓, PGE2↓, TNF-α↓, IL1β↓, IL6↓, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, DNAdam↑, Cyt‑c↑, RadioS↑, RAS↓, BBB↑, BioAv↓, Half-Life↝, Half-Life↝, toxicity↓,
7860- isoO,    Metabolism and plasma pharmacokinetics of isoorientin, a natural active ingredient, in Sprague-Dawley male rats after oral and intravenous administration
Half-Life↝, BioAv↓,
2180- itraC,    Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
- Review, Var, NA
Dose↝, toxicity↝, BioAv↑, Half-Life↝, BioAv↑, Dose↝, HH↓, TumAuto↑, Akt↓, mTOR↓, angioG↓, MDR1↓, TumCP↓, eff↑,
8047- IVM,    The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
- Review, Var, NA
Half-Life↝, MDR1↓, P-gp/ABCB1↓, mtDam↑, ROS↑, OCR↓, compI↓, MMP↓, mt-SOD↑, ATP↓, p‑Akt↓, p‑mTOR↓, eff↓, ICD↑, TumAuto↑, PAK1↓, Wnt↓, TCF↓, Nanog↓, SOX2↓, CSCs↓, CD44↓, CD24↓, Dose↝,
8341- LDN,    Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy
- Review, Var, NA
OGFr↑, TumCP↓, TumCCA↑, Apoptosis↑, toxicity↝, Half-Life↝, *FasL↓, *Fas↓, BAX↑, Casp9↑, Casp3↑, Bcl-2↓, survivin↓, PI3K↓, PDK1 / PDPK1↓, mTOR↓, ChemoSen↑, chemoP↑, eff↑, QoL∅,
2922- LT,    Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC
- in-vitro, Liver, HUH7
Half-Life↝, TumCCA↑, AKT1↓, ATF2↓, NF-kB↓, GSK‐3β↓, cMyc↓, GSTs↓, TrxR1↓, ROS↑,
2543- M-Blu,    The use of methylene blue to control the tumor oxygenation level
- in-vivo, Lung, NA
OCR↑, OXPHOS↑, Half-Life↝, AntiTum↑,
5796- MET,    Tumor, whole blood, plasma, and tissue concentrations of metformin in lung cancer patients
- Human, Lung, NA
selectivity↑, AMPK↑, Risk↓, Half-Life↝, ChemoSen↑,
4643- OLE,  HT,    Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine
- Review, Var, NA
TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP/DDIT3↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27/CDKN1B↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,
3247- PBG,    Bioavailability and In Vivo Antioxidant Activity of a Standardized Polyphenol Mixture Extracted from Brown Propolis
- Review, NA, NA
Half-Life↝, BioAv↓, Half-Life↝, BioAv↓,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP/DDIT3↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp/ABCB1↓, MDR1↓, MRP1/ABCC1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2/PTGS2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
4693- PTS,    Pterostilbene in the treatment of inflammatory and oncological diseases
BioAv↑, *Inflam↓, *antiOx↑, AntiTum↑, BBB↑, Half-Life↝, *ROS↓, *NRF2↑, *NQO1↑, *HO-1↑, PTEN↑, miR-19b↓, TumCCA↑, ER Stress↑, PERK↑, ATF4↑, CHOP/DDIT3↑, Ca+2↝, EMT↓, NF-kB↓, Twist↓, Vim↓, E-cadherin↑, ChemoSen↑, toxicity∅, toxicity↝,
3055- RES,    Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets
- Review, Var, NA
BioAv↓, BioAv↓, Dose↑, eff↑, eff↑, Dose↑, BioAv↑, ROS↑, MMP↓, P21↑, p27/CDKN1B↑, TumCCA↑, ChemoSen↑, COX2/PTGS2↓, 5LO↓, VEGF↓, IL1↓, IL6↓, IL8↓, AR↓, PSA↓, MAPK↓, Hif1a↓, Glycolysis↓, miR-21↓, PTEN↑, Half-Life↝, *IGF-1↓, *IGFBP3↑, Half-Life↓,
3063- RES,    Resveratrol: A Review of Pre-clinical Studies for Human Cancer Prevention
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiAg↑, *chemoPv↑, ChemoSen↑, BioAv↑, Half-Life↝, COX2/PTGS2↓, cycD1/CCND1↓, CDK2↓, CDK4↓, CDK6↓, P21↑, MMP9↓, NF-kB↓, Telomerase↓, PSA↓, MAPK↑, P53↑,
2442- RES,    High absorption but very low bioavailability of oral resveratrol in humans
- in-vitro, Nor, NA
BioAv↝, Half-Life↝, BioAv↓, eff↝,
1744- RosA,    Therapeutic Applications of Rosmarinic Acid in Cancer-Chemotherapy-Associated Resistance and Toxicity
- Review, Var, NA
chemoR↓, ChemoSideEff↓, RadioS↑, ROS↓, ChemoSen↑, BioAv↑, Half-Life↝, antiOx↑, ROS↑, Fenton↑, DNAdam↑, Apoptosis↑, CSCs↓, HH↓, Bax:Bcl2↑, MDR1↓, P-gp/ABCB1↓, eff↑, eff↑, FOXO4↑, *eff↑, *ROS↓, *JNK↓, *ERK↓, *GSH↑, *H2O2↑, *MDA↓, *SOD↑, *HO-1↑, *CardioT↓, selectivity↑,
2549- SDT,    Landscape of Cellular Bioeffects Triggered by Ultrasound-Induced Sonoporation
- Review, Var, NA
sonoP↑, tumCV↓, MMP↓, ROS↑, Ca+2↑, eff↝, eff↑, selectivity↑, Half-Life↝, Dose↝, P-gp/ABCB1↓, ER Stress↑, other↑,
3293- SIL,    Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer
- Review, Var, NA
hepatoP↑, TumMeta↓, Inflam↓, chemoP↑, radioP↑, Half-Life↝, *GSTs↑, p‑JNK↑, BAX↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, eff↑, TumCCA↑, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, Casp3↑, Casp9↑, eff↑, CXCR4↓, Dose↝,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27/CDKN1B↑, COX2/PTGS2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1/SREBF1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
3041- SK,    Promising Nanomedicines of Shikonin for Cancer Therapy
- Review, Var, NA
Glycolysis↓, TAMS↝, BioAv↓, Half-Life↝, P21↑, ERK↓, ROS↑, GSH↓, MMP↓, TrxR↓, MMP13↓, MMP2↓, MMP9↓, SIRT2↑, Hif1a↓, PKM2↓, TumCP↓, TumMeta↓, TumCI↓,
965- SK,    Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW-620
Hif1a↓, ROS↓, mTOR↓, p70S6↓, 4E-BP1↓, eIF2α↓, TumCCA↑, TumCP↓, Half-Life↝,
5078- SSE,  Rad,    Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer
- Trial, Pca, NA
Half-Life↝, OS↑, Pain↓, PSA↓, GSH↓, ROS↑, selectivity↑, TumCG↓, AR↓, Dose↑, ChemoSen↑, RadioS↑,

Showing Research Papers: 1 to 50 of 54
Page 1 of 2 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 54

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

OGFr↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 1,   Catalase↓, 1,   compI↓, 1,   Fenton↑, 2,   GSH↓, 4,   GSTs↓, 1,   H2O2↑, 1,   HO-1↑, 1,   ICD↑, 1,   NOX4↑, 1,   NRF2↓, 1,   NRF2↑, 2,   OXPHOS↑, 1,   Prx4↑, 1,   ROS↓, 4,   ROS↑, 21,   SIRT3↓, 1,   SIRT3↑, 1,   mt-SOD↑, 1,   SOD2↓, 1,   Thiols↓, 1,   TrxR↓, 2,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ABL1↓, 1,   ATP↓, 2,   MMP↓, 11,   mtDam↑, 3,   OCR↓, 1,   OCR↑, 1,   c-Raf↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACLY↓, 1,   AKT1↓, 1,   AMPK↑, 4,   ATG7↑, 1,   cMyc↓, 3,   FASN↓, 2,   GlucoseCon↓, 1,   Glycolysis↓, 4,   HK2↓, 1,   HMG-CoA↓, 1,   IDH1↓, 1,   lactateProd↓, 1,   NADPH↓, 1,   PDK1 / PDPK1↓, 3,   PKM2↓, 1,   PPARγ↑, 1,   SIRT1↓, 1,   SIRT2↑, 1,   SREBP1/SREBF1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 7,   p‑Akt↓, 4,   Apoptosis↑, 8,   ATF2↓, 1,   BAD↑, 1,   Bak↑, 2,   BAX↑, 5,   Bax:Bcl2↑, 1,   Bcl-2↓, 7,   Bcl-xL↓, 2,   Casp↑, 2,   Casp1↑, 1,   Casp3↑, 11,   Casp7↑, 2,   Casp8↑, 2,   Casp9↑, 9,   Cyt‑c↓, 1,   Cyt‑c↑, 4,   Diablo↑, 1,   DR5↑, 1,   iNOS↓, 1,   JNK↑, 3,   p‑JNK↑, 1,   MAPK↓, 3,   MAPK↑, 1,   Mcl-1↓, 2,   Mcl-1↑, 1,   p27/CDKN1B↑, 4,   p‑p38↑, 1,   Pyro↑, 1,   survivin↓, 5,   Telomerase↓, 2,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

cSrc↓, 1,   EF-1α↓, 1,   p70S6↓, 2,   p‑p70S6↓, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   cJun↑, 1,   H3↑, 1,   H4↑, 1,   HATs↑, 2,   miR-21↓, 1,   other↑, 1,   other↝, 1,   other∅, 1,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 4,   cl‑CHOP/DDIT3↑, 1,   eIF2α↓, 1,   eIF2α↑, 1,   ER Stress↑, 7,   GRP78/BiP↑, 2,   HSP27↓, 1,   HSP70/HSPA5↓, 1,   HSP90↓, 1,   IRE1↑, 1,   PERK↑, 2,   UPR↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   LC3II↑, 1,   TumAuto↑, 3,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 4,   DNMTs↓, 1,   P53↑, 6,   PARP↓, 1,   PARP↑, 1,   cl‑PARP↑, 8,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 3,   CDK4↓, 6,   cycD1/CCND1↓, 7,   cycE/CCNE↓, 2,   P21?, 1,   P21↓, 1,   P21↑, 7,   p‑RB1↓, 2,   TumCCA↑, 16,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   CD133↓, 1,   CD24↓, 1,   CD44↓, 2,   cFos↓, 1,   CIP2A↓, 1,   CSCs↓, 4,   EMT↓, 6,   EMT↑, 1,   ERK↓, 5,   p‑ERK↓, 1,   FOXO4↑, 1,   Gli1↓, 1,   GSK‐3β↓, 2,   HDAC↓, 2,   HDAC2↓, 1,   HDAC3↓, 1,   HH↓, 3,   IGF-1↓, 1,   IGFBP3↑, 1,   miR-34a↑, 1,   mTOR↓, 9,   p‑mTOR↓, 1,   mTORC1↓, 2,   Nanog↓, 2,   Nestin↓, 1,   NOTCH↓, 2,   NOTCH1↓, 2,   NOTCH3↓, 1,   OCT4↓, 1,   PI3K↓, 6,   PTCH1↓, 1,   PTEN↑, 4,   RAS↓, 2,   Shh↓, 1,   SOX2↓, 2,   Src↓, 1,   STAT1↓, 1,   STAT3↓, 7,   STAT3↑, 1,   p‑STAT3↓, 1,   STAT6↓, 1,   TCF↓, 1,   TumCG↓, 5,   Wnt↓, 5,  

Migration(tgid=13) ⓘ

5LO↓, 1,   AntiAg↑, 1,   AP-1↓, 1,   CA↓, 1,   Ca+2↑, 3,   Ca+2↝, 1,   E-cadherin↑, 3,   FAK↓, 2,   FAK↑, 1,   miR-19b↓, 1,   miR-203↑, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 4,   MMP9↓, 8,   MMPs↓, 1,   N-cadherin↓, 1,   PAK1↓, 1,   PDGF↓, 2,   SOX4↓, 1,   SOX4↑, 1,   TGF-β↓, 2,   Treg lymp↓, 1,   TumCI↓, 6,   TumCMig↓, 5,   TumCP↓, 9,   TumMeta↓, 6,   Twist↓, 2,   uPA↓, 3,   Vim↓, 3,   Zeb1↓, 2,   β-catenin/ZEB1↓, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 8,   ATF4↑, 3,   ATF4↝, 1,   EGFR↓, 3,   Hif1a↓, 6,   Hif1a↝, 1,   NO↑, 1,   TAMS↓, 1,   TAMS↝, 1,   VEGF↓, 8,   VEGFR2/KDR/Flk1↓, 3,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 4,   GLUT1↓, 1,   NHE1↓, 1,   P-gp/ABCB1↓, 5,   sonoP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 9,   CXCR4↓, 2,   ICAM-1↓, 1,   IKKα↓, 1,   IL1↓, 2,   IL1β↓, 2,   IL2↓, 1,   IL6↓, 4,   IL8↓, 2,   Inflam↓, 4,   JAK1↓, 1,   JAK2↓, 1,   NF-kB↓, 14,   p65↓, 2,   PD-L1↓, 1,   PGE2↓, 5,   PSA↓, 4,   TLR4↓, 1,   TLR4↝, 1,   TNF-α↓, 4,   TNF-α↑, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↑, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 3,   CDK6↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 25,   BioAv↑, 17,   BioAv↝, 9,   BioEnh↑, 1,   chemoR↓, 1,   ChemoSen↑, 15,   Dose↑, 5,   Dose↝, 18,   eff↓, 1,   eff↑, 20,   eff↝, 3,   Half-Life↓, 4,   Half-Life↝, 62,   MDR1↓, 4,   MRP1/ABCC1↓, 1,   RadioS↑, 7,   selectivity↑, 11,   selectivity∅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 3,   E6↓, 1,   E7↓, 1,   EGFR↓, 3,   IL6↓, 4,   PD-L1↓, 1,   PSA↓, 4,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   AntiCan↑, 2,   AntiTum↑, 3,   cardioP↑, 1,   chemoP↑, 4,   chemoPv↑, 1,   ChemoSideEff↓, 2,   hepatoP↑, 2,   NP/CIPN↑, 1,   OS↑, 3,   Pain↓, 1,   QoL∅, 1,   radioP↑, 1,   Risk↓, 1,   toxicity↓, 1,   toxicity↝, 11,   toxicity∅, 2,   TumVol↓, 2,  
Total Targets: 294

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 6,   ARE↑, 1,   Catalase↑, 1,   GSH↑, 3,   GSTs↑, 1,   H2O2↑, 1,   HO-1↑, 4,   MDA↓, 2,   NQO1↑, 1,   NRF2↑, 4,   ROS↓, 8,   SOD↑, 3,   SOD1↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

p‑cMyc↑, 1,   LDL↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Fas↓, 1,   FasL↓, 1,   JNK↓, 1,   TRPV1↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   ERK↑, 1,   IGF-1↓, 1,   IGFBP3↑, 1,   neuroG↑, 1,   STAT↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 3,   TIMP1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL8↓, 1,   Inflam↓, 11,   NF-kB↓, 2,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 5,   Dose↝, 4,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiCan↑, 2,   cardioP↑, 2,   CardioT↓, 1,   chemoP↑, 1,   chemoPv↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 3,   Pain↓, 1,   toxicity↓, 3,   toxicity↝, 2,   Weight↓, 1,  
Total Targets: 52

Scientific Paper Hit Count for: Half-Life, Half-Life
3 Chlorogenic acid
3 EGCG (Epigallocatechin Gallate)
3 Honokiol
3 Resveratrol
3 Selenite (Sodium)
2 Cynara scolymus/Globe Artichoke/Artichoke Extract
2 Cucurbitacin
2 Fisetin
2 Silymarin (Milk Thistle) silibinin
2 Shikonin
1 Auranofin
1 Astragalus
1 Ashwagandha(Withaferin A)
1 Arsenic trioxide
1 Atorvastatin
1 Betulinic acid
1 Bromelain
1 Capsaicin
1 Carvacrol
1 Caffeic acid
1 Ferulic acid
1 Curcumin
1 Dasatinib/Phyrago
1 Dichloroacetate
1 Diclofenac
1 Dandelion Root
1 Aspirin
1 Geraniol
1 HydroxyCitric Acid
1 isoorientin
1 itraconazole
1 Ivermectin
1 low dose naltrexone
1 Luteolin
1 Methylene blue
1 Metformin
1 Oleuropein
1 HydroxyTyrosol
1 Propolis -bee glue
1 Piperlongumine
1 Pterostilbene
1 Rosmarinic acid
1 SonoDynamic Therapy UltraSound
1 Radiotherapy/Radiation
1 Urolithin
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:1109  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page